BMO Capital Markets analyst Etzer Darout in a note to investors said the insurance fraud probe represents a “headline risk” ...

AstraZeneca may be emphasizing the potential for combination treatments to help its obesity pipeline stand out from the crowd, but the Big Pharma insists it is still “playing to win” in the space.

Over the past three years, additional insurance fraud cases have emerged involving AstraZeneca employees in various Chinese regions. The investigation focuses on potential breaches of data privacy ...

AstraZeneca is a company with a turbulent history ... consultancy who had been instructed by its chief executive, Sir David Barnes, to find a name which was memorable, had no associations with ...

AstraZeneca disclosed Wednesday that Leon Wang, a high-ranking executive who oversees international operations and is also president of its subsidiary in China, is under investigation by Chinese ...

As AstraZeneca’s chronic obstructive pulmonary disease drug Breztri continues climbing toward blockbuster status, the Big Pharma is broadening its efforts to support people with COPD.

The U.K. pharmaceutical company AstraZeneca has become the largest multinational drugmaker in China, drawing 13% of its $5.8 billion in revenue last year from there, against a backdrop of an acute ...

AstraZeneca Plc said its experimental obesity pill was well tolerated by patients with type-2 diabetes as it presented data from several studies testing its three new weight-loss medicines. The ...

David Ignatius writes a twice-a-week foreign affairs column for The Washington Post. Ignatius has written 12 spy novels: “Phantom Orbit” (2024), “The Paladin” (2020), “The Quantum Spy ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...